149 related articles for article (PubMed ID: 1663731)
1. Effects of phosphonylmethoxyalkyl-purine and -pyrimidine derivatives on TK+ and TK- HSV-1 keratitis in rabbits.
Maudgal PC; De Clercq E
Antiviral Res; 1991 Jul; 16(1):93-100. PubMed ID: 1663731
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of (S)-HPMPA against thymidine kinase-deficient herpes simplex virus-keratitis.
Maudgal PC; De Clercq E; Huyghe P
Invest Ophthalmol Vis Sci; 1987 Feb; 28(2):243-8. PubMed ID: 8591903
[TBL] [Abstract][Full Text] [Related]
3. (S)-1-(3-hydroxy-2-phosphonyl-methoxypropyl)cytosine in the therapy of thymidine kinase-positive and -deficient herpes simplex virus experimental keratitis.
Maudgal PC; De Clercq E
Invest Ophthalmol Vis Sci; 1991 May; 32(6):1816-20. PubMed ID: 1851733
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of 9-(2-phosphonylmethoxyethyl)adenine in the therapy of TK+ and TK- herpes simplex virus experimental keratitis.
Maudgal PC; De Clercq E
Curr Eye Res; 1991; 10 Suppl():139-42. PubMed ID: 1650660
[TBL] [Abstract][Full Text] [Related]
5. Phosphonylmethoxyalkyl purine and pyrimidine derivatives for treatment of opportunistic cytomegalovirus and herpes simplex virus infections in murine AIDS.
De Castro LM; Kern ER; De Clercq E; Ghaffar A; Mayer EP; Vogt PE; Gangemi JD
Antiviral Res; 1991 Jul; 16(1):101-14. PubMed ID: 1663726
[TBL] [Abstract][Full Text] [Related]
6. Comparative activity of various compounds against clinical strains of herpes simplex virus.
Andrei G; Snoeck R; Goubau P; Desmyter J; De Clercq E
Eur J Clin Microbiol Infect Dis; 1992 Feb; 11(2):143-51. PubMed ID: 1327785
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of phosphonylmethoxyalkyl derivatives of adenine in experimental herpes simplex virus and vaccinia virus infections in vivo.
De Clercq E; Holý A; Rosenberg I
Antimicrob Agents Chemother; 1989 Feb; 33(2):185-91. PubMed ID: 2719463
[TBL] [Abstract][Full Text] [Related]
8. Trifluridine, cidofovir, and penciclovir in the treatment of experimental herpetic keratitis.
Kaufman HE; Varnell ED; Thompson HW
Arch Ophthalmol; 1998 Jun; 116(6):777-80. PubMed ID: 9639447
[TBL] [Abstract][Full Text] [Related]
9. In vitro selection of drug-resistant varicella-zoster virus (VZV) mutants (OKA strain): differences between acyclovir and penciclovir?
Andrei G; De Clercq E; Snoeck R
Antiviral Res; 2004 Mar; 61(3):181-7. PubMed ID: 15168799
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine in various models of herpes simplex virus infection in mice.
De Clercq E; Holý A
Antimicrob Agents Chemother; 1991 Apr; 35(4):701-6. PubMed ID: 2069375
[TBL] [Abstract][Full Text] [Related]
11. Experimental thymidine kinase-deficient HSV-1 keratitis: therapeutic attempts.
Maudgal PC; De Clercq E; Huyghe P
Curr Eye Res; 1987 Apr; 6(4):579-84. PubMed ID: 2953558
[TBL] [Abstract][Full Text] [Related]
12. Effects of phosphonylmethoxyalkyl derivatives studied with a murine model for abortion induced by equine herpesvirus 1.
Awan AR; Field HJ
Antimicrob Agents Chemother; 1993 Nov; 37(11):2478-82. PubMed ID: 8285638
[TBL] [Abstract][Full Text] [Related]
13. Metabolic diversity and antiviral activities of acyclic nucleoside phosphonates.
Aduma P; Connelly MC; Srinivas RV; Fridland A
Mol Pharmacol; 1995 Apr; 47(4):816-22. PubMed ID: 7723743
[TBL] [Abstract][Full Text] [Related]
14. Successful treatment of progressive mucocutaneous infection due to acyclovir- and foscarnet-resistant herpes simplex virus with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC).
Snoeck R; Andrei G; Gérard M; Silverman A; Hedderman A; Balzarini J; Sadzot-Delvaux C; Tricot G; Clumeck N; De Clercq E
Clin Infect Dis; 1994 Apr; 18(4):570-8. PubMed ID: 8038312
[TBL] [Abstract][Full Text] [Related]
15. Cidofovir and experimental herpetic stromal disease.
Kaufman HE; Varnell ED; Thompson HW
Arch Ophthalmol; 1999 Jul; 117(7):925-8. PubMed ID: 10408458
[TBL] [Abstract][Full Text] [Related]
16. Comparative antiviral efficacies of cidofovir, trifluridine, and acyclovir in the HSV-1 rabbit keratitis model.
Romanowski EG; Bartels SP; Gordon YJ
Invest Ophthalmol Vis Sci; 1999 Feb; 40(2):378-84. PubMed ID: 9950596
[TBL] [Abstract][Full Text] [Related]
17. Properties of a 9-(2-phosphonylmethoxyethyl)adenine (PMEA)-resistant herpes simplex virus type 1 virus mutant.
Vonka V; Anisimová E; Cerný J; Holý A; Rosenberg I; Votruba I
Antiviral Res; 1990 Aug; 14(2):117-21. PubMed ID: 2177316
[TBL] [Abstract][Full Text] [Related]
18. Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines.
De Clercq E; Sakuma T; Baba M; Pauwels R; Balzarini J; Rosenberg I; Holý A
Antiviral Res; 1987 Dec; 8(5-6):261-72. PubMed ID: 3451698
[TBL] [Abstract][Full Text] [Related]
19. HPMPC, a broad-spectrum topical antiviral agent, inhibits herpes simplex virus type 1 replication and promotes healing of dendritic keratitis in the New Zealand rabbit ocular model.
Gordon YJ; Romanowski EG; Araullo-Cruz T
Cornea; 1994 Nov; 13(6):516-20. PubMed ID: 7842711
[TBL] [Abstract][Full Text] [Related]
20. Activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) against guinea pig cytomegalovirus infection in cultured cells and in guinea pigs.
Li SB; Yang ZH; Feng JS; Fong CK; Lucia HL; Hsiung GD
Antiviral Res; 1990 May; 13(5):237-52. PubMed ID: 2168690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
